EGFR T790M Mutation and Lung Cancer Risk in Non-Smokers

_{“New research links a rare inherited EGFR T790M mutation to higher lung cancer risk in nonsmokers.”}

Lung cancer is often associated with smoking. But thousands of people who have never smoked are diagnosed with the disease every year.

New research published in Science on September 17, 2026, has identified a rare inherited mutation that may help explain why some nonsmokers develop lung cancer. The mutation, known as EGFR T790M, appears to substantially increase lung cancer risk, particularly among people who have never smoked.

What did the new study discover?

Researchers from Dana-Farber Cancer Institute and the 23andMe Research Institute analyzed genetic and health information from more than 3.3 million people.

They found that people carrying an inherited EGFR T790M mutation had about a 25-fold higher risk of lung cancer compared with people without the mutation.

Among people who had never smoked, the association was even stronger. Carriers had roughly 60 to 62 times the risk of lung cancer compared with nonsmoking non-carriers.

That does not mean that every person carrying the mutation will develop lung cancer. The researchers caution that the study does not provide a precise lifetime probability for an individual carrier.

The mutation itself is extremely uncommon. Researchers estimate that it occurs in roughly one in 15,000 to 16,000 people in the U.S. It appears to be more concentrated in parts of Southern Appalachia, where researchers identified a possible historical founder effect.

Why is EGFR T790M important?

EGFR, or epidermal growth factor receptor, is a gene involved in signals that control cell growth.

The T790M variant is unusual because it can be inherited, meaning it can be present in a person’s cells from birth and potentially passed through families.

Earlier research had already connected inherited EGFR T790M with lung cancer. However, the mutation is so rare that scientists previously lacked a sufficiently large population database to accurately estimate its prevalence and associated risk.

The new study provides that larger-scale evidence.

Lung cancer can affect nonsmokers too

The discovery is important because smoking is not the only lung cancer risk factor.

According to the U.S. Centers for Disease Control and Prevention, approximately 10% to 20% of lung cancers in the United States occur among people who never smoked or smoked fewer than 100 cigarettes during their lifetime. Other possible contributors include secondhand smoke, radon, air pollution, asbestos and inherited genetic changes.

This means the absence of a smoking history does not completely eliminate lung cancer risk.

Could genetic testing change lung cancer screening?

This is where the research becomes particularly interesting.

Current U.S. screening recommendations are still primarily based on age and smoking history. The U.S. Preventive Services Task Force recommends annual low-dose CT screening for adults aged 50 to 80 who have at least a 20 pack-year smoking history and currently smoke or quit within the previous 15 years.

The CDC also states that routine lung cancer screening is not currently recommended for people who have never smoked because the potential harms of screening can outweigh the benefits in that population.

The new genetic findings do not immediately change those recommendations.

Instead, they raise an important question: Should people with certain inherited genetic risks eventually receive personalized lung cancer screening even if they have never smoked?

Researchers are now investigating that possibility.

The INHERIT Study is examining people with inherited genetic risks for lung cancer, with the goal of improving screening, prevention and treatment strategies.

What should people take from this research?

The biggest message is not that everyone needs genetic testing or regular CT scans.

It is that lung cancer is more complicated than smoking history alone.

For people with a strong family history of lung cancer, particularly when cases occur among nonsmokers, discussing family history and genetic counseling with a qualified healthcare professional may become increasingly relevant as research develops.

The EGFR T790M discovery also highlights the growing role of precision medicine. Instead of treating every person’s cancer risk in the same way, researchers are moving toward identifying genetic and environmental factors that could help determine who may benefit from earlier or more personalized monitoring.

For now, the evidence is promising but still developing. The next challenge is determining exactly how genetic risk should translate into safe, effective screening.

Important: This research does not mean that people who never smoke should routinely undergo genetic testing or CT scans. Screening decisions should be discussed with a qualified healthcare professional based on personal and family history and established clinical guidelines.

#LungCancer #EGFRMutation #LungCancerInNonsmokers #GeneticHealth #CancerResear

References / Sources